Treatment with APS could significantly decrease the expression levels of Foxp3 and CD4+CD25high on Tregs (P<0.05), and the down-regulatory effect of APS was observed to manifest in a dose-dependent fashion. The gene discussed is FOXP3; the disease is autoimmune polyendocrinopathy.